Declassifying Psychedelic Drugs to Examine their Treatment Potential
Psychiatrist and honorary lecturer at the Institute of Psychiatry, Psychology and Neuroscience, at King’s College London, James Rucker, MRCPsych, is proposing to reclassify and improve access to psychedelics in order to conduct more research on their therapeutic benefits.
He believes in the potential of psychedelics so much that late last month he took to the pages of the prestigious journal the British Medical Journal to make his case. He wrote that psychedelics should instead be considered Schedule II substances which would allow a “comprehensive, evidence based assessment of their therapeutic potential.” “The Western world is facing an epidemic of mental health problems with few novel therapeutic prospects on the horizon,” Rucker told Psychiatry Advisor, justifying why studying psychedelics for treating psychiatric illnesses is so important.
Original Article (Psychiatry Advisor):
Declassifying Psychedelic Drugs to Examine their Treatment Potential
Artwork Fair Use: American Society of Consultant Pharmacists and MED-PASS
